Streptococcus

Health Professionals Urged To Attend NH Symposium On The Latest Breakthroughs For Neuropsychiatric Disorders Triggered By Strep And Other Infections

Retrieved on: 
Thursday, September 15, 2022
Union Church (Portsmouth, Rhode Island), Dartmouth–Hitchcock Medical Center, Inflammation, Infection, Cytokine, Strep, Nursing, Brain, Mycoplasma, Biomarker, Hospital, Immunology, Massachusetts General Hospital, Genetics, Physician, OCD, Tic, Treating, Disorder, Neuropsychiatry, Anxiety, Doctor of Philosophy, Science, Pediatrics, Insurance, Research, Parent, Awareness, Multimedia, Immune system, PANDAS, Education, View, Medicine, Pharmaceutical industry, Streptococcus

PORTSMOUTH, N.H., Sept. 15, 2022 /PRNewswire/ -- Rapid onset of OCD, anxiety, and tics in children and young adults can be triggered by a strep (streptococcal) infection, however, the underlying cause is not widely recognized or treated, according to researchers and physicians who specialize in post-infectious neuropsychiatric disorders called PANDAS (Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus) and PANS (Pediatric Acute-onset Neuropsychiatric Syndrome).

Key Points: 
  • The symposium, entitled PANDAS/PANS: Recognizing, Understanding and Treating Immune-Mediated Neuropsychiatric Disorders, will share new advances and provide an opportunity for clinicians to discuss improving early detection and treatment.
  • To register visit https://thealexmanfullfund.org/symposium/
    Attendance is limited to physicians, psychologists, nurses, mental health professionals, researchers, policymakers, and others involved in the treatment, education, research, or funding related to such disorders.
  • In addition, the latest research on the role of genetics, the microbiome, and cytokines will also be presented.
  • Ongoing research is bringing us closer to achieving our goal of quickly identifying post infectious neuropsychiatric illnesses and finding a cure."

FDA Grants Breakthrough Therapy Designation to Pfizer’s Group B Streptococcus Vaccine Candidate to Help Prevent Infection in Infants Via Immunization of Pregnant Women

Retrieved on: 
Wednesday, September 7, 2022
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, European Medicines Agency, Streptococcus, CPS, COVID-19, Bill, Safety, The Journal of Infectious Diseases, NYSE, Immunization, Ageing, Research, Breakthrough therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food and Drug Administration, Death, Vaccine, YouTube, News, Disease, Pneumonia, Fetus, PFE, Placenta, GBS, Pregnancy, Food, LinkedIn, Senior, Science, Infant, Valence (chemistry), Mother, Review, Bill & Melinda Gates Foundation, Infection, U.S. Securities and Exchange Commission, Journal, Stillbirth, Centers for Disease Control and Prevention timeline, Antibody, Inc., Streptococcus agalactiae, FDA, Twitter, Facebook, Sepsis, Â, World Health Organization, Clinical trial, Risk, Meningitis, Bacteria, Life, Pharmaceutical industry, Medical device, Pfizer

Group B Streptococcus (GBS) is a common bacterium that can cause potentially devastating diseases in infants, including sepsis, pneumonia and meningitis, during the first three months of life.

Key Points: 
  • Group B Streptococcus (GBS) is a common bacterium that can cause potentially devastating diseases in infants, including sepsis, pneumonia and meningitis, during the first three months of life.
  • Vaccines given to pregnant women (maternal immunization) that are intended to prevent illness in young infants rely on this process of transplacental antibody transfer.
  • A Novel Hexavalent Capsular Polysaccharide Conjugate Vaccine (GBS6) for the Prevention of Neonatal Group B Streptococcal Infections by Maternal Immunization.
  • Group B Streptococcus infection causes an estimated 150,000 preventable stillbirths and infant deaths every year.

Vaxcyte Completes Enrollment of Phase 2 Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults 65 Years and Older

Retrieved on: 
Tuesday, September 6, 2022
Mortality, Security (finance), OPA, Public health, Subclinical infection, Safety, PCV, Vaccination, Disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SAN, Death, Vaccine, Streptococcus, Streptococcus pneumoniae, Immunoglobulin G, Pneumonia, Immunodeficiency, Infection, Achievement, Incidence, Bacteria, Food, Private Securities Litigation Reform Act, SEC, Chemistry, U.S. Securities and Exchange Commission, Meningitis, Antigen, Otitis media, Periodontal disease, Ageing, Fast Track, Trial of the century, PD, GLOBE, Company, FDA, Peterborough, Adult, Risk, Sutro Biopharma, Genetically modified bacteria, IPD, Review, Sinusitis, Pharmaceutical industry, Tutoring, COVID-19, Pneumococcal conjugate vaccine

SAN CARLOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced the completion of enrollment in the Phase 2 study evaluating VAX-24 in healthy adults 65 years of age and older. VAX-24 is the Company’s lead, 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD).

Key Points: 
  • This Phase 2 clinical study, which is now fully enrolled with approximately 200 participants, is a randomized, observer-blind, dose-finding study designed to evaluate the safety, tolerability and immunogenicity of VAX-24 in adults 65 years of age and older.
  • Vaxcyte expects to announce topline safety, tolerability and immunogenicity results from this Phase 2 study in the first half of 2023.
  • VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults Aged 18-64 (VAX-24 Study 101, NCT05266456):
    This is a randomized, observer-blind, dose-finding, controlled study designed to evaluate the safety, tolerability and immunogenicity of VAX-24 in healthy adults 18-64 years of age.
  • VAX-24 Phase 2 Clinical Study in Adults Aged 65 and Older (VAX-24 Study 102, NCT05297578):
    This is a randomized, observer-blind, dose-finding, controlled study designed to evaluate the safety, tolerability and immunogenicity of VAX-24 in healthy adults 65 years of age and older.

SINOVAC Approved to Initiate Clinical Trial for Its Omicron Containing COVID-19 Vaccine in Chile

Retrieved on: 
Tuesday, September 6, 2022
Research, Infectious Diseases, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Valence (chemistry), COVID-19, CEO, Safety, Program, Influenza A virus subtype H1N1, WHO, NASDAQ, Vaccine, Streptococcus, R, Infection, H5N1, Instituto Butantan, HFMD, Polio, Chickenpox, Hepatitis A, Mumps, ISP, Company, Foot-and-mouth disease virus, RNA transfection, Clinical trial, Delta, EV71, Sinovac Biotech, Omicron

In this phase II randomized, double-blind, multicenter clinical trial, 826 fully vaccinated adults will be recruited.

Key Points: 
  • In this phase II randomized, double-blind, multicenter clinical trial, 826 fully vaccinated adults will be recruited.
  • Mr. Weidong Yin, the Chairman, President, and CEO of SINOVAC said, SINOVAC has made great progress collaborating with global partners in the development and manufacturing of the COVID-19 vaccine.
  • Its COVID-19 vaccine, CoronaVac, has been approved for use in more than 60 countries and regions worldwide.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.

Blue Water Vaccines Reports Second Quarter 2022 Financial Results and Recent Business Highlights

Retrieved on: 
Monday, August 15, 2022
Hospital, Instituto Butantan, Income, Mouse, BWV, GLOBE, Technology strategy, Congress, Research, Cincinnati Children's Hospital Medical Center, Company, Infection, Norovirus, Center, Epitope, Bacteria, Streptococcus pneumoniae, Vaccine, Gastroenteritis, G&A, NTNUI, Rotavirus, Technology, Moraxella catarrhalis, University, Water, S&P, AOM, Antigen, Development, Administration, University of Oxford, Life insurance, Pharmaceutical industry, Online gambling, Health insurance, Streptococcus

Closed private placement in April 2022, with net proceeds of approximately $6.9 million

Key Points: 
  • Closed private placement in April 2022, with net proceeds of approximately $6.9 million
    Signed multiple strategic agreements and collaborations to further vaccine candidate research, development, and manufacturing
    $22.2 million in cash as of June 30, 2022
    CINCINNATI, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Blue Water Vaccines Inc. (BWV or Blue Water Vaccines or the Company) today announced its financial results for the second quarter ended June 30, 2022 and provided an update on recent business developments and progress.
  • Blue Water Vaccines is a pre-clinical stage biotechnology company developing vaccines against multiple infectious diseases, including acute otitis media (AOM) from Streptococcus pneumoniae colonization, influenza, norovirus, and rotavirus.
  • Blue Water Vaccines had several exciting updates in the second quarter of 2022, as we raised additional capital to support development of our vaccine pipeline, said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water Vaccines.
  • On April 19, 2022, the Company closed a private placement with aggregate net cash proceeds of approximately $6.9 million.

Pfizer Announces Positive Top-Line Results from Phase 3 Study of 20-Valent Pneumococcal Conjugate Vaccine in Infants

Retrieved on: 
Friday, August 12, 2022
Research, FDA, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Irritability, OPA, Series, NYSE, Senior, Immunoglobulin G, Population, GMC Terrain, Clinical trial, Inc., Streptococcus, PFE, Pain, Fever, Pneumococcal conjugate vaccine, Streptococcus pneumoniae, Vaccine, Safety, Somnolence, Vaccination, Appetite, Infant, NI, Development, IPD, Food, Swelling, Pharmaceutical industry, Pfizer

Phase 3 study (NCT04382326) in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population.

Key Points: 
  • Phase 3 study (NCT04382326) in infants evaluating its 20-valent pneumococcal conjugate vaccine candidate (20vPnC) for the prevention of invasive pneumococcal disease (IPD) caused by the 20 Streptococcus pneumoniae (pneumococcus) serotypes contained in the vaccine for the pediatric population.
  • We are grateful to everyone who made this study possible, including the study investigators and in particular the trial participants and their parents/guardians for their contribution to this important research.
  • Overall, the safety profile of the 20vPnC candidate was consistent with Prevnar 13 given in the same schedule.
  • In 2020, Pfizer initiated the Phase 3 clinical trial program for the pediatric indication for 20vPnC.

Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones

Retrieved on: 
Monday, August 8, 2022
MSD, U.S. Securities and Exchange Commission, GLOBE, Investment, PDX, Security (finance), Research, Patient, Lymphatic system, Multiple myeloma, Endometrial cancer, Bevacizumab, National Medical Products Administration, Merck Group, Private Securities Litigation Reform Act, Protein engineering, Merck, IADC, DNA, Biotechnology, Safety, Lymphoid leukemia, ADC, Forward-looking statement, BCMA, ROR1, STRO, NSCLC, BMS, Neoplasm, NHL, COVID-19, Large-cell lung carcinoma, Cancer, Streptococcus, Goal, B-cell lymphoma, Fast Track, Bristol Myers Squibb, FDA, Merck Serono, IND, Company, Twitter, Depreciation, Control, NASDAQ, MM, Investor, Sutro, EMD, Serono, Pharmaceutical industry, Cryptocurrency, Fine chemical, Birth control, Vaccine, Tasly, Astellas Pharma

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the quarter ended June 30, 2022, its recent business highlights, and a preview of anticipated select milestones.

Key Points: 
  • Sutro expects to report additional data on efficacy, safety, and durability from the dose-expansion cohort, together with the design of a potential registrational study, in the second half of 2022.
  • As of June 30, 2022, Sutro held approximately 1.6 million shares of Vaxcyte common stock, with a fair value of $34.0 million.
  • Total operating expenses for the quarter ended June 30, 2022 were $47.5 million, as compared to $37.9 million for the same period in 2021.
  • Sutro Biopharma, Inc., headquartered in South San Francisco, is a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs).

Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

Retrieved on: 
Thursday, August 4, 2022
U.S. Securities and Exchange Commission, GLOBE, Death, SEC, Success, Streptococcus, Security (finance), Communication, Plasma protein binding, Patient, Infection, PCV, Peterborough, Periodontal disease, Collection, Streptococcus pneumoniae, IPD, Overalls, Food, Disease, Immunodeficiency, Fast track (FDA), Sinusitis, SAN, Safety, Priority review, Meningitis, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Trial of the century, Mortality, Pneumonia, Incidence, Subclinical infection, Vaccine, Vaccination, Genetically modified bacteria, Chemistry, Fast Track, FDA, Sutro Biopharma, Private Securities Litigation Reform Act, Population, PD, IND, Separate, Ageing, Achievement, Pneumococcal conjugate vaccine, Review, Otitis media, Company, Bacteria, Â, Drug discovery, Antigen, Pharmaceutical industry, COVID-19

SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to VAX-24, the Company’s 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), in adults ages 18 and older. The Fast Track designation is an FDA process that has been designed to facilitate the development and expedite the review of drugs, including vaccines, that treat or prevent serious conditions and fill an unmet medical need.

Key Points: 
  • The Company also completed a successful pre-Investigational New Drug (IND) meeting with the FDA regarding the VAX-24 pediatric program.
  • Vaxcyte is deploying this approach with VAX-24 in order to add more pneumococcal strains without compromising the overall immune response.
  • Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases.
  • Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked.

Invasive Pneumococcal Disease Epidemiology and Market Forecast 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 4, 2022
Health, Pharmaceutical, Diagnosis, Streptococcus pneumoniae, Disease, Research, Report, Streptococcus, Awareness, Vaccine, Medical device, Medical imaging, Pharmaceutical industry, Epidemiology

The "Invasive Pneumococcal Disease - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Invasive Pneumococcal Disease - Market Insight, Epidemiology and Market Forecast -2032" report has been added to ResearchAndMarkets.com's offering.
  • This "Invasive Pneumococcal Disease - Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Invasive Pneumococcal Disease, historical and forecasted epidemiology as well as the Invasive Pneumococcal Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The Invasive Pneumococcal Disease market report provides current treatment practices, emerging drugs, Invasive Pneumococcal Disease market share of the individual therapies, current and forecasted Invasive Pneumococcal Disease market Size from 2019 to 2032 segmented by seven major markets.
  • The report covers the descriptive overview of Invasive Pneumococcal Disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
    Additionally, an all-inclusive account of both the current and emerging therapies for Invasive Pneumococcal Disease are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
    A detailed review of Invasive Pneumococcal Disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM
    The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Invasive Pneumococcal Disease market
    In the coming years, Invasive Pneumococcal Disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
    The companies and academics are working to assess challenges and seek opportunities that could influence Invasive Pneumococcal Disease R&D.

SINOVAC COVID-19 Vaccine Approved for Use in Children Above 6 months of Age in Hong Kong

Retrieved on: 
Wednesday, August 3, 2022
Biotechnology, Pharmaceutical, General Health, Health, COVID-19, Children, Infectious Diseases, Consumer, NASDAQ, Vaccine, Safety, Foot-and-mouth disease virus, Minor, Department, R, Program, Center, Health Bureau, H5N1, WHO, Scientific Committee on Antarctic Research, Infection, HFMD, Sinovac Biotech, Mumps, III, Scientific Committee on Emerging and Newly Identified Health Risks, Polio, Chickenpox, Hepatitis A, COVID-19, CoronaVac, Company, EV71, Carrie Lam as Chief Executive of Hong Kong, Vaccination, Streptococcus, COVID-19 vaccine, Ageing, Zoonosis, Influenza A virus subtype H1N1, Government

The vaccination schedule for this age group follows the same vaccination schedule of older children.

Key Points: 
  • The vaccination schedule for this age group follows the same vaccination schedule of older children.
  • SINOVAC initiated its COVID-19 vaccine (CoronaVac) phase III clinical studies among children aged 6 months to 17 years since 2021.
  • Preliminary results show the vaccine has a good safety and immunogenicity profile, with no severe adverse reaction reported 6 months after two doses of vaccination among children aged 6 months to 35 months.
  • SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities.